Identifying blood and tissue markers for tumor hypoxia in head and neck and lung cancers

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to identify and confirm new blood and tissue markers that indicate tumor hypoxia, a condition linked to increased tumor spread and resistance to treatment in head and neck and lung cancers. The research focuses on validating the prognostic significance of specific proteins, such as osteopontin, and monitoring their levels during therapy and follow-up. Additionally, the study seeks to establish a gene and protein signature associated with hypoxia in affected patients.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Histologically confirmed squamous cell carcinoma of the head and neck sites or non-small cell lung cancer, or relatives of patients with histologically confirmed squamous cell carcinoma of the head and neck.
* Able to sign a Stanford IRB approved consent form

Exclusion criteria:

* Refuse or unable to sign an IRB approved consent form.
* Refuse to be contacted in the future for follow up.

Where it's running

• Stanford University School of Medicine
  Stanford, California, United States Recruiting

Study contacts

• Principal investigator: Quynh-Thu Le — Stanford University
• Study coordinator: Eyiwunmi Laseinde
• Email: Rad-onc-ccto@lists.stanford.edu

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Does the time of day for PD-1/PD-L1 therapy affect response in NSCLC and HNSCC

  In people with advanced NSCLC or resectable head and neck cancer, this study tests whether receiving PD-1/PD-L1 therapy in the morning versus the afternoon changes treatment outcomes.

  Recruiting Phase 2 UNC Lineberger Comprehensive Cancer Center · Chapel Hill, North Carolina · NCT07630168

• Blood extracellular vesicles to detect chemotherapy-related nerve damage.

  We will test whether tiny blood particles called extracellular vesicles can predict who will develop chemotherapy-induced peripheral neuropathy in adults receiving taxane, platinum, or antimitotic chemotherapy.

  Recruiting Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico · Milan · NCT07558447

• High-precision detection of leftover cancer using a liquid-biopsy platform (SHERLOCK)

  This project will test whether sensitive blood and other fluid tests for circulating tumor DNA can find leftover cancer (minimal residual disease) in adults treated with curative intent for breast, lung, melanoma, gynecologic, or genitourinary cancers.

  Recruiting University Health Network, Toronto · Toronto, Ontario · NCT07524114

• EPI-326 for EGFR-mutant non-small cell lung cancer and head and neck squamous cell carcinoma

  This phase 1 trial will try EPI-326, a new drug, in people with EGFR-mutant non‑small cell lung cancer or advanced head and neck squamous cell carcinoma to find safe doses, study how the body handles it, and look for early signs it shrinks tumors.

  Recruiting at 8 sites Phase 1 EpiBiologics · Los Angeles, California and 7 other locations · NCT07462377

• Riluzole to prevent thinking and memory problems during chemotherapy

  This pilot trial tests whether riluzole can prevent thinking and memory problems in adults with cancer receiving anthracycline- or platinum-based chemotherapy.

  Recruiting Phase 2 University of California, Irvine · Orange, California · NCT07447050

• Collecting blood and leftover tumor tissue to test molecular residual disease (MRD) detection

  This project will test whether blood and leftover tumor tissue from adults with certain solid tumors can be used with Natera's MRD blood tests to find tiny amounts of cancer (ctDNA) after treatment.

  Recruiting Natera, Inc. · Austin, Texas · NCT07318051

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.